Stockreport

Agios: Novo's Sickle Cell Win Changes The PK Activator Game (Rating Downgrade) [Seeking Alpha]

Novo Nordisk A/S  (NVO) 
Last novo nordisk a/s earnings: 2/5 01:31 am Check Earnings Report
US:NYSE Investor Relations: novonordisk.com/investors.html
PDF Novo Nordisk's PK activator looks better than AGIO's mitapivat in sickle cell disease, meeting both co-primary endpoints and intensifying competitive pressure. Aqvesm [Read more]